You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 275 No. 15, April 17, 1996 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Maternal Immunization With Haemophilus influenzae Type b Polysaccharide—Tetanus Protein Conjugate Vaccine in The Gambia

Kim Mulholland, FRACP; Rahaman O. Suara, MBBS; George Siber, MD; Don Roberton, MD; Shabbar Jaffar, MSc; Jainaba N'Jie, MSc; Lindsey Baden, MD; Claudette Thompson; Raana Anwaruddin; Leonie Dinan; W. Paul Glezen, MD; Nicholas Francis, MRCPath; Bernard Fritzell, MD; Brian M. Greenwood, FRCP

JAMA. 1996;275(15):1182-1188.


Abstract

Objective.
—To evaluate maternal responses to Haemophilus influenzae type b (Hib) polysaccharide—tetanus protein conjugate vaccine (polyribosylribitol phosphate—tetanus or PRP-T) given to pregnant Gambian women, the transplacental transfer of antibody, and the effect of maternal immunization on infant responses to the vaccine.

Design.
—An open, randomized immunogenicity study.

Setting.
—A busy urban health center in The Gambia.

Study participants.
—A total of 451 pregnant women enrolled during the third trimester of pregnancy.

Intervention.
—Study participants were randomized to three groups. In one group, mothers were given PRP-T during the third trimester and their infants were given PRP-T at 2, 3, and 4 months of age. In the second group, mothers received PRP-T and infants were given inactivated poliovirus vaccine. In the third group, mothers received meningococcal A and C vaccine, and their infants received PRP-T.

Main Outcome Measures.
—Anti-PRP antibody measurements of maternal, cord, and infant blood.

Results.
—Vaccinated women had a marked increase in total anti-PRP antibody (geometric mean titer, 9.0 µg/mL), which was greatest in women in their first or second pregnancy. Previous tetanus vaccination during the same pregnancy and high concentrations of antitetanus antibody were associated with lower anti-PRP responses. In infants of PRP-T recipients, cord blood anti-PRP IgG concentrations were 61% of simultaneous maternal concentrations. In vaccinated infants of vaccinated mothers, geometric mean anti-PRP antibody concentrations at birth, 2 months of age, and 5 months of age were 1.92, 0.35, and 2.84 µg/mL, respectively, while in vaccinated infants of unvaccinated mothers, the corresponding concentrations were 0.29, 0.12, and 3.91 µg/mL. At 2 months of age, 60% of infants of vaccinated mothers and 26% of infants of unvaccinated mothers had anti-PRP antibody concentrations considered to be protective (>0.15 µg/mL).

Conclusions.
—In areas where much invasive Hib disease occurs in infants younger than 6 months, maternal immunization may help to reduce the risk of Hib disease in infants too young for immunization.

(JAMA. 1996;275:1182-1188)



Author Affiliations

From the Medical Research Council Laboratories, Fajara, The Gambia (Drs Mulholland, Suara, Baden, and Greenwood and Mr Jaffar and Ms N'Jie); Dana-Farber Cancer Institute, Boston, Mass (Dr Siber and Mss Thompson and Anwaruddin); Department of Paediatrics, University of Adelaide (Australia) (Dr Roberton and Ms Dinan); Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Dr Glezen); Department of Histopathology, Charing Cross and Westminster Medical School, London, England (Dr Francis); and Pasteur Merieux Sérums et Vaccins, Marnes-la-Coquette, France (Dr Fritzell).


Footnotes

Reprints: Kim Mulholland, FRACP, CDR/ARI, WHO, 1211 Geneva 27, Switzerland.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Influence of Mycobacteriumbovis Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination
Ota et al.
J. Immunol. 2002;168:919-925.
ABSTRACT | FULL TEXT  

Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates
Peltola
Clin. Microbiol. Rev. 2000;13:302-317.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.